153 related articles for article (PubMed ID: 29386312)
1. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
2. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.
Mi S; Lin M; Brouwer-Visser J; Heim J; Smotkin D; Hebert T; Gunter MJ; Goldberg GL; Zheng D; Huang GS
Clin Cancer Res; 2016 Sep; 22(18):4676-86. PubMed ID: 27121792
[TBL] [Abstract][Full Text] [Related]
3. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.
Huang F; Tanaka H; Knudsen BS; Rutgers JK
BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
[TBL] [Abstract][Full Text] [Related]
4. Gynecological carcinosarcomas: Overview and future perspectives.
Collet L; González López AM; Romeo C; Méeus P; Chopin N; Rossi L; Rowinski E; Serre AA; Rannou C; Buisson A; Treilleux I; Ray-Coquard I
Bull Cancer; 2023 Nov; 110(11):1215-1226. PubMed ID: 37679206
[TBL] [Abstract][Full Text] [Related]
5. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract][Full Text] [Related]
6. First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene.
Rosa RCA; Yurchenko AA; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Kannouche PL; Nikolaev S; Ferraz VEF
Genet Mol Biol; 2020; 43(4):e20200100. PubMed ID: 33001133
[TBL] [Abstract][Full Text] [Related]
7. The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity.
Labrousse G; Vande Perre P; Parra G; Jaffrelot M; Leroy L; Chibon F; Escudie F; Selves J; Hoffmann JS; Guimbaud R; Lutzmann M
NAR Cancer; 2023 Jun; 5(2):zcad011. PubMed ID: 36915289
[TBL] [Abstract][Full Text] [Related]
8. POLE-mutated Endometrial "Carcinosarcoma".
De Boeck A; Nohr E; El-Hallani S; Ghatage P; Lee CH; Köbel M
Int J Gynecol Pathol; 2024 May; ():. PubMed ID: 38833721
[TBL] [Abstract][Full Text] [Related]
9. Brain Metastasis in a Young Patient with Uterine Carcinosarcoma.
Katiyar V; Araujo T; Farooq MZ; Vohra I; Gupta S
Cureus; 2019 Jun; 11(6):e5010. PubMed ID: 31497440
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Carcinosarcoma Mimicking Symptoms of Recurrent Diverticulitis: A Case Report.
Phyu R; Patrizio HA; Schachter T
Cureus; 2024 Apr; 16(4):e57948. PubMed ID: 38738152
[TBL] [Abstract][Full Text] [Related]
11. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
[TBL] [Abstract][Full Text] [Related]
12. Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
VanderLaan PA; Rangachari D; Majid A; Parikh MS; Gangadharan SP; Kent MS; McDonald DC; Huberman MS; Kobayashi SS; Costa DB
Lung Cancer; 2018 Feb; 116():90-95. PubMed ID: 29413057
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.
Fiorica F; Belluomini L; Stefanelli A; Santini A; Urbini B; Giorgi C; Frassoldati A
Am J Clin Oncol; 2018 Nov; 41(11):1101-1105. PubMed ID: 29389733
[TBL] [Abstract][Full Text] [Related]
14. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ; Lemons JM; Karrison TG; Pitroda SP; Melotek JM; Zha Y; Al-Hallaq HA; Arina A; Khodarev NN; Janisch L; Chang P; Patel JD; Fleming GF; Moroney J; Sharma MR; White JR; Ratain MJ; Gajewski TF; Weichselbaum RR; Chmura SJ
J Clin Oncol; 2018 Jun; 36(16):1611-1618. PubMed ID: 29437535
[TBL] [Abstract][Full Text] [Related]
15. High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.
Bao H; Bai T; Takata K; Yokobori T; Ohnaga T; Hisada T; Maeno T; Bao P; Yoshida T; Kumakura Y; Honjo H; Sakai M; Sohda M; Fukuchi M; Altan B; Handa T; Ide M; Miyazaki T; Ogata K; Oyama T; Shimizu K; Mogi A; Asao T; Shirabe K; Kuwano H; Kaira K
Oncol Lett; 2018 Mar; 15(3):3061-3067. PubMed ID: 29435038
[TBL] [Abstract][Full Text] [Related]
16. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
[TBL] [Abstract][Full Text] [Related]
18. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
19. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
20. Guillain-Barré-like syndrome during pembrolizumab treatment.
Ong S; Chapman J; Young G; Mansy T
Muscle Nerve; 2018 Feb; ():. PubMed ID: 29443381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
